ADC-Pertuzumab Promising as New Standard in HER2-Positive Metastatic Breast Cancer

By News Health
2 days Ago

(MedPage Today) — CHICAGO — First-line trastuzumab deruxtecan (T-DXd) combined with pertuzumab (Perjeta) improved progression-free survival (PFS) in HER2-positive locally advanced or metastatic breast cancer, according to the DESTINY-Breast09…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115844

Author :

Publish date : 2025-06-02 12:00:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Crafty cockatoos learn to use public drinking fountains

Former HHS Chief Blasts Trump's Enablers, Says Policies Will Cost Lives

Undetectable Disease Status in Myeloma Similar With Drug Therapy, Transplantation

Trump Administration Revokes Federal Guidance Protecting Emergency Abortions

Myeloma Trial Results Spark Talk of 'Potential Cure'

'Immediately Practice-Changing' Trial in Small Cell Lung Cancer